InvestorsHub Logo
Followers 49
Posts 4433
Boards Moderated 0
Alias Born 03/20/2012

Re: None

Tuesday, 09/12/2017 12:27:39 AM

Tuesday, September 12, 2017 12:27:39 AM

Post# of 108192
Cantor Fitzgerald Thinks Advaxis' Stock is Going to Recover
September 11, 2017

Goldstein observed: "Refining Development Plan. With its 3Q17 EPS report, ADXS also laid out a strategic focus based on four development programs. As a result, the company will not undertake new trials in HPV-associated head and neck cancer and anal cancer programs beyond the ongoing trials, but instead plans to look to partnerships for further development. Additionally, the company will no longer pursue HER2 disease. Instead, ADXS plans to direct resources to cervical and prostate cancer, ADXS-NEO and ADXS-HOT. We like the idea of focusing the portfolio, and ADXS has chosen areas where the company has both critical mass and novel technology, in our view." ...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News